Reuters logo
BRIEF-Inovio initiates Phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers
2017年4月24日 / 下午1点20分 / 7 个月前

BRIEF-Inovio initiates Phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers

April 24 (Reuters) - Inovio Pharmaceuticals Inc:

* Inovio initiates phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers

* Plans to initiate a phase 3 study of VGX-3100 as a treatment for high grade cervical dysplasia in 2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below